Lastly, treatment with recombinant SP-D may alleviate ARDS severity in humans based on the current literature, but there is a lack of preclinical research aimed primarily at assessing the efficacy and safety of SP-D. Here, SFTPD is linked to acute respiratory distress syndrome.